Wolters Kluwer Health
may email you for journal alerts and information, but is committed
to maintaining your privacy and will not share your personal information without
your express consent. For more information, please refer to our Privacy Policy.

Background: Acellular dermal matrix has been increasingly accepted in prosthetic breast reconstruction. Observed benefits include improved control and support of implant position, better implant coverage, and the suggestion of a decreased capsular contracture rate. Based on this positive experience, it is not surprising that acellular dermal matrix would be applied to other challenging implant-related problems. This study investigates the use of acellular dermal matrix for correction or prevention of implant-associated breast deformities.

Methods: Patients who underwent primary aesthetic breast surgery or secondary aesthetic or reconstructive breast surgery using acellular dermal matrix and implants between November of 2003 and October of 2009 were reviewed retrospectively. Patient demographics, indications for acellular dermal matrix, and acellular dermal matrix type and inset pattern were identified. Preoperative and postoperative photographs, success or failure of the procedure, complications, and need for related or unrelated revision surgery were recorded.

Conclusion: Based on this experience in 77 breasts, acellular dermal matrix has shown promise in treating and preventing capsular contracture, rippling, implant malposition, and soft-tissue thinning.

Washington, D.C.; and Los Angeles, Calif.

From the Department of Plastic Surgery, Georgetown University Hospital, and the David Geffen School of Medicine at the University of California, Los Angeles.

Received for publication April 18, 2010; accepted August 13, 2010.

Presented in part at the 26th Annual Meeting of the Northeastern Society of Plastic Surgeons, in Charleston, South Carolina, September 23 through 27, 2009, and the 2010 Plastic Surgery Senior Residents Conference, in Anaheim, California, January 20 through 23, 2010.

Disclosure:Dr. Spear is a paid consultant for LifeCell and Allergan. Dr. Teitelbaum is a consultant for LifeCell, Allergan, and Kythera Biopharmaceuticals. Dr. Nahabedian is on the speaker's bureau for LifeCell. Drs. Clemens and Seruya have no financial interest in any of the products, devices, or drugs mentioned in this article.

Some error has occurred while processing your request. Please try after some time.

Email to a Colleague

Colleague's E-mail is Invalid

Your Name: (optional)

Your Email:

Colleague's Email:

Separate multiple e-mails with a (;).

Message:

Send a copy to your email

Your message has been successfully sent to your colleague.

Some error has occurred while processing your request. Please try after some time.

Add Item(s) to:

An Existing Folder

A New Folder

Folder Name:

Description:

The item(s) has been successfully added to "".

David H. Song, M.D., M.B.A. is the President-elect of the American Society of Plastic Surgeons (ASPS). He is a consultant with BioMet, Emmi Solutions, LLC, a consortium-member providing senior debt for Brava, and consultant with and investor in HealthEngine.com. He receives author royalties from Elsevier. Scot Glasberg, M.D. is the President of the American Society of Plastic Surgeons (ASPS). He is a consultant with LifeCell Corp and Mentor Corp and an investor with Strathspey Crown. The authors have no sources of funding to report related to the writing or submission of this discussion.

The location and affiliation information should read as follows: Arlington Heights, Ill. From the American Society of Plastic Surgeons/Plastic Surgery Foundation.